Shingles vaccines may reduce dementia risk, two large new studies ... - CNN
WEBJul 30, 2024 · CNN — Two new studies suggest that getting a vaccine to protect against a painful case of shingles may be beneficial for memory, too. An estimated 98% of US adults have had chickenpox and are at...
GSK Announces Positive Topline Data on Co-Administration of …
WEB6 days ago · Indication for SHINGRIX SHINGRIX is an FDA-approved vaccine for the prevention of shingles (herpes zoster) in: Adults 50 years and older. Adults 18 years and older who are or will be at increased ...
New long-term data show SHINGRIX continues to provide high
WEBApr 17, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with SHINGRIX (Recombinant Zoster Vaccine or RZV).
GSK Announces Positive Topline Data on Co-Administration of
WEB6 days ago · About SHINGRIX (Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of shingles in adults 50 and over. It combines an antigen, glycoprotein E, ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect ...
New shingles vaccine could reduce risk of dementia
WEBJul 25, 2024 · The new recombinant shingles vaccine ‘Shingrix’ is associated with a reduced risk of dementia compared to an earlier shingles vaccine, according to a major new study published in Nature Medicine. It is also …
Large study of shingles vaccine finds strong effectiveness over 4 …
WEBJan 8, 2024 · Shingrix is a vaccine that uses recombinant technology and has been the recommended shingles vaccine in the U.S. since 2017 for people aged 50 and older. In 2021, the CDC Advisory Committee on Immunization Practices voted to recommend Shingrix to immunocompromised people ages 19 years or older.
Two-dose shingles vaccine is still highly effective after four years
WEBApr 1, 2024 · The CDC recommends adults ages 50 and older get two doses of the recombinant zoster vaccine (Shingrix), with the doses separated by two to six months, to prevent shingles. But how long can it offer protection?
New data show Shingrix can provide at least 10 years of ... - GSK
WEBOct 19, 2022 · GSK plc (LSE/NYSE: GSK) today announced positive interim results from the ZOSTER-049 extension study showing that overall Shingrix (Zoster Vaccine Recombinant, Adjuvanted) can provide at least a decade of protection against shingles (herpes zoster) after initial vaccination.
Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based ...
WEBFeb 10, 2023 · NEW YORK and MAINZ, GERMANY, FEBRUARY 10, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicel...
Shingrix approved in the US for prevention of shingles in ...
WEBJul 26, 2021 · GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or who will be at increased risk of shingles due to immunodeficiency or immunosuppression caused …
Skip to content